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ABSTRACT 
 
Patients with advanced heart failure (NYHA FC III and IV heart failure) had positive cardiac troponin levels in previous cohort 
studies. In heart failure, cardiac troponin T (cTnT) is a biomarker that is sensitive to myocardial damage, especially 
myocardial necrosis. However, there is still little information regarding changes in cTnT levels during standard therapy. This 
prospective observational study is aimed at evaluating changes in cTnT levels before and after the administration of standard 
therapy and evaluating symptom improvement before and after the administration of standard therapy in patients with severe 
heart failure. Measurement of cTnT levels and symptom improvement parameters before treatment was carried out on the first 
day of the inpatient and measurement after therapy was carried out on the last day of the inpatient. Sampling was done by 
consecutive sampling and found 30 patients in the inpatient room of the SMF Cardiovascular Disease, Dr. Soetomo Hospital, 
Surabaya during the months of May-July 2017. The results of the study obtained the average cTnT levels before therapy 33.48 
+ 31.88 pg/ml and the average cTnT levels after therapy 46.32 + 52.68 pg/ml. Based on the statistical difference test with the 
Wilcoxon sign-ranked test, there was no significant change in cTnT levels (p = 0.318). On the parameter of clinical symptom 
improvement, there was a significant decrease in pulse, respiratory rate, blood pressure, and mean arterial pressure before and 
after administration of therapy (p <0.05). There was no change in troponin T levels before and after the administration of 
therapy meant there was no worsening of myocardial necrosis. 
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ABSTRAK 
 
Pasien dengan gagal jantung berat (gagal jantung NYHA FC III dan IV) memiliki kadar troponin jantung yang positif pada 
penelitian kohort sebelumnya. Pada gagal jantung, troponin T jantung (cTnT) merupakan biomarker yang sensitif pada 
kerusakan miokard khususnya nekrosis miokard. Namun, masih sedikit informasi mengenai perubahan kadar cTnT selama 
pemberian terapi standar. Penelitian observasional prospektif ini ditujukan untuk mengevaluasi perubahan kadar cTnT 
sebelum dan setelah pemberian terapi standar dan mengevaluasi perbaikan gejala sebelum dan setelah pemberian terapi 
standar pada pasien gagal jantung berat. Pengukuran kadar cTnT dan parameter perbaikan gejala sebelum terapi dilakukan 
pada hari pertama pasien rawat inap dan pengukuran setelah terapi dilakukan pada hari terakhir pasien rawat inap. 
Pengumpulan sampel dilakukan dengan consecutive sampling dan didapatkan 30 pasien di ruang rawat inap SMF Penyakit 
Jantung dan Pembuluh Darah RSUD Dr. Soetomo Surabaya selama bulan Mei-Juli 2017. Hasil penelitian diperoleh rerata 
kadar cTnT sebelum terapi 33,48 + 31,88 pg/ml dan rerata kadar cTnT setelah terapi 46,32 + 52,68 pg/ml. Berdasarkan uji 
beda secara statistik dengan Wilcoxon sign-ranked test tidak didapatkan perubahan kadar cTnT yang signifikan (p = 0,318). 
Pada parameter perbaikan gejala klinis terjadi penurunan yang signifikan antara nadi, laju pernafasan, tekanan darah dan 
tekanan arteri rata-rata sebelum dan setelah pemberian terapi (p < 0,05). Tidak terdapat perubahan kadar troponin T sebelum 
dan setelah pemberian terapi berarti tidak terdapat perburukan dari nekrosis miokard.  
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INTRODUCTION 
 
Heart failure is a complex clinical syndrome and is the 
result of structural and functional disorders of 
ventricular filling and expulsion. The main 
manifestations of heart failure are tightness and fatigue 
which can limit exercise tolerance and fluid retention, 
causing lung and/or splenic congestion and peripheral 
edema (Yancy et al 2013). Heart failure becomes a 
significant public health problem related to mortality, 
morbidity and health care costs especially in patients 
aged> 65 years (Roger 2013). After patients 
hospitalized with heart failure, patients have a high risk 
of returning admission with a 25% return on admission 
at 1 month (Krumholz et al 2012). 
 
Currently the severe heart failure population (NYHA 
FC III and IV) has a 1-year mortality rate of around 
50% and requires therapeutic intervention. Treatment 
options for advanced heart failure include a combination 
of drugs, mechanical devices, and surgical procedures 
that can improve symptoms and survival (Friedrich & 
Bohm 2007). Based on studies of risk stratification 
using a combination of troponin T and brain natriuretic 
peptide in 93 patients with class III and IV heart failure, 
troponin T levels >33 pg/ml when Admission is 
associated with an increased risk of cardiac death (Ishii 
et al 2002). 
 
The goal of heart failure therapy is to reduce morbidity 
and mortality (PERKI 2015). Administration of ACEI, 
ARB, beta blockers and aldosterone antagonists aims to 
improve morbidity and mortality while administration 
of diuretics, digitalis, transient inotropes and certain 
antiarrhythmias aims to control symptoms (Hunt 2005, 
Swedberg et al 2005). The standard therapy given 
includes ACEI, beta blockers, aldosterone antagonists, 
ARBs and diuretics (Yancy et al 2013, PERKI 2015). 
 
BNP and NT-proBNP are considered as benchmarks of 
heart failure biomarkers compared to others (Gaggin & 
Januzzi 2015). Based on The Trial of TIME-CHF 
Randomized Trial (Pfisterer et al 2009) showed that 
heart failure therapy based on NT-BNP did not improve 
the overall clinical outcome or QoL (Quality of Life) 
compared to symptom-based therapy. Although 
symptom improvement is also the goal of therapy, 
symptom improvement is not the same as significant 
improvement in morbidity and mortality (Cotter et al 
2005). 
 
Increased levels of Troponin T are associated with 
higher hospital mortality, ejection fraction and lower 
systolic pressure, increased need for inotropics, longer 
intensive care (Singh et al 2015). Troponin levels in 
acute heart failure are higher than chronic heart failure 
and the percentage detected troponin T levels are higher 
than troponin I in chronic heart failure (Kociol et al 
2010). 
 
In the analysis of troponin T in patients with acute heart 
failure, showed a decrease in troponin T levels is a 
response to therapy and return to compensation 
conditions. Unchanged troponin T levels indicate a 
steady state of decompensation and a longer duration of 
hospital stay (Ferreira et al 2014). Based on this 
background, through this study we want to analyze how 
much changes in troponin T levels before and after the 
administration of standard therapy in patients with heart 
failure by taking into account the parameters of the 
improvement of the patient's clinical condition. 
 
 
MATERIALS AND METHODS 
 
This research is a prospective observational study with 
consecutive sampling techniques. In this study, 
researchers did not intervene in the therapeutic subjects. 
Subjects were adult (> 18 years) class III and IV heart 
failure patients who had symptoms of heart failure for 
more than 9 hours and were willing to sign information 
to consent. The study was conducted on inpatients at the 
heart and blood vessel disease SMF Dr.Soetomo 
Regional Hospital. 
 
Patients with severe renal failure (creatinine clearance 
<30 ml/min), acute myocardial infarction, sepsis and 
pulmonary embolism were excluded from this study. 
The number of research subjects was 30 patients and 
cTnT levels were measured twice, that is before therapy 
or on the first day of hospitalization and after therapy or 
on the last day of hospitalization. Patients also recorded 
clinical condition parameters, including heart rate, 
respiratory rate (RR), blood pressure, mean arterial 
pressure (MAP), input volume and output volume of the 
body. 
 
Measurement of cTnT levels was carried out by taking 2 
ml of the patient's blood in a serum separator tube on 
the first and last day of hospitalization. Analysis of 
serum cTnT levels using the ELISA method and Human 
cTnT/TNNT2 reagents (Troponin T type 2, cardiac) 
ELISA KIT (Elabscience, Italy). The study was 
conducted in May-July 2017. Analysis of changes in 
levels and improvement of clinical symptoms of 
patients was carried out statistically with the Wilcoxon 
signed-rank test for non-parametric data while the 
Paired T-test for parametric data to the differential test. 
Ethical clearance test by the Ethics Committee 
Dr.Soetomo Surabaya Public Hospital and has obtained 
information on ethical eligibility. 
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RESULTS 
 
Patient demographic data are listed in Table 1. From the 
demographic data, the mean age of patients was 55.13 + 
11.17 years. The youngest age of the patient is 31 years 
and the oldest is 74 years. By age category, the largest 
group of patients was 50-59 while the patient group was 
at least> 70 years old. Most of the research subjects 
were male, 16 patients (53.3%) while the rest were 
female 14 patients (46.7%). 
 
Patients have various clinical characteristics on the first 
day of hospitalization. Characteristics of these clinical 
conditions include classes of heart failure, shortness 
before hospitalization, ejection fraction, kidney function 
and comorbid patients. 
 
Table 1. Patients’ demographic data 
 
Variables n (%) or mean 
+ SD 
Age  
- 30 – 39 years old 
- 40 – 49 years old 
- 50 – 59 years old 
- 60 – 69 years old 
- > 70 years old 
Sex 
- Male 
- Female 
55.13 + 11.17 
5   (16.7) 
3   (10.0) 
11  (36.7) 
10 (33.3) 
1 
 
16 (53.3) 
14 (46.7) 
 
The characteristics of drug therapy given to patients are 
presented in Table 5.3, including: diuretics, aldosterone 
antagonists, angiotensin-converting enzyme inhibitors 
(ACEI), angiotensin II type I receptor blockers (ARB), 
beta blockers, digitalis, ISDN, warfarin, amiodarone and 
inotropic (dopamine and dobutamine). 
 
Of the 30 patients subjected to the study, 10 patients 
(33.3%) had a history of drug therapy and regularly took 
medication while 20 patients (66.7%) did not have a 
history of drug therapy or did not take medication 
regularly. Kinds of history of drug therapy can vary 
from patient to patient. Blood sampling for each patient 
for measurement of serum troponin T (cTnT) levels was 
carried out twice, namely on the first day of 
hospitalization (before administration of therapy) and 
finally of hospitalization (after administration of 
therapy). 
 
The mean serum cTnT level before administration of 
therapy was 33.48 + 31.88 pg/ml with a minimum level 
of 9.27 pg/ml and a maximum level of 141.99 pg/ml. 
The mean serum cTnT level after administration of 
therapy was 46.32 + 52.68 pg/ml with a minimum level 
of 5.59 pg/ml and a maximum level of 187.40 pg/ml. 
The cut off point of cTnT is 12 pg/ml (Latini, et al., 
2007) and serum cTnT levels prior to the administration 
of therapy that exceeded this value were 28 patients 
(93.3%). Based on the average serum cTnT levels and 
clinical symptoms before and after administration of 
therapy showed improvement in clinical symptoms not 
accompanied by a decrease in serum cTnT levels. 
 
Before hospitalization, there was a history of taking the 
patient's medication therapy which was also observed 
during the study. Patients said taking medication 
regularly and there was a history of medication during 
outpatient care in the medical record showed patients 
were obedient and regularly took medication. Patients 
do not routinely take medication if the patient says he 
has never taken medication or not routinely taking 
medication before. During hospitalization, patients get 
standard therapy ranging from 1-5 kinds of standard 
therapy drugs. Based on variations in the standard 
therapy of each patient, can be grouped into 6 variants 
with each consisting of 5 patients. 
 
Mean cTnT serum levels from each variant and mean 
serum levels of adherence taking medication were then 
displayed to find out whether therapeutic and adherence 
variation factors influenced changes in troponin T 
levels. There was a decrease in levels in the variant 
group (Fur + Spi + Cap/Val +/- Bis) and (Fur + Spi + 
Lis +/- Val +/- Bus). There was a decrease in levels in 
patients who regularly took medication (10 patients) 
whereas in patients who did not routinely take drugs 
there was an increase in levels (20 patients). 
 
Serum cTnT levels before and after administration of 
therapy based on significance did not change (p = 
0.318), but based on the average results of both there 
were increased levels. This shows that the increase in 
cTnT levels before and after therapy is not significant. 
In the parameters of the clinical symptoms of pulse, RR, 
systolic blood pressure, diastolic blood pressure, and 
MAP there are changes based on mean values and 
statistical tests with a significance of p <0.05. This 
shows the clinical improvement after the administration 
of therapy was declared significant. Changes in and out 
of fluid based on the results of the mean decreases but 
the change is not significant (p> 0.05). 
 
 
DISCUSSION 
 
This study aims to analyze standard therapy for heart 
failure by measuring changes in serum troponin T levels 
and improvement of symptoms (blood pressure, MAP, 
pulse, RR, volume of fluid in and out) before and after 
standard therapy. The study was conducted on 30 
patients with NYHA FC III and IV heart failure who 
were treated at the IRNA of the Heart and Blood 
Vessels of RSUD Dr. Soetomo Surabaya. The mean age 
of patients was 55.13 + 11.17 years with an age range of 
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31-74 years. More male patients than female patients. 
Based on epidemiological studies in Spain with 88,195 
patients have an average age of 77 years and the 
majority of women, but in patients younger than 74 
years the prevalence of men is higher than women 
(Farre et al 2011). Estrogen plays a role in women 
before menopause by preventing the activation of 
RAAS (the renin-angiotensin-aldosterone system). If 
menopause is associated with ovarian estrogen loss, 
pathogenesis of diastolic dysfunction will occur, 
resulting in an increase in angiotensin II and NOS 
(nitric oxidase synthase), and ROS (reactive oxygen 
species) that contribute to hypertension (Zhao et al 
2014). 
 
 
Table 2. Profile characteristics of clinical conditions of research subjects 
 
Variables n (%) or mean + SD Min Max 
Heart Failure Class 
- NYHA FC III 
- NYHA FC IV 
Shortness before hospitalization (days) 
- 1 day 
- >1 day 
Length of stay (days) 
- <5 days 
-> 5 days 
Ejection Faction (%) 
- HFrEF (<40%) 
- HFpEF (>40%) 
Creatinine serum (mg/dl) 
- <1 mg/dl 
-> 1 mg/dl 
estimated GFR (ml/minute/1.73m2) 
- 30-59 ml/minute/1.73m2 
-> 60 ml/minute/1.73m2 
Comorbid (each patient) 
- Ischemic cardiomyopathy 
- Valvular heart disease 
- Diabetes mellitus type II 
- Coronary heart disease 
Old Myocard Infarct 
- Rheumatic heart disease 
- Atrial fibrillation 
- hypertension 
- Left ventricular thrombus 
- Post cardiogenic shock 
Improvement of symptoms 
- Admission heart rate (x/minute) 
- Discharge heart rate (x/minute) 
- RR Admission (x/minute) 
- RR Discharge (x/minute) 
- Admission systolic pressure (mmHg) 
- Discharge systolic pressure (mmHg) 
- Admission diastolic pressure (mmHg) 
- Discharge diastolic pressure (mmHg) 
- MAP Admission (mmHg) 
- MAP Discharge (mmHg) 
- Admission inlet fluid volume (ml) 
- Admission fluid volume out (ml) 
- The volume of fluid entering the Discharge (ml) 
- Discharge liquid volume out (ml) 
 
16 (53.3) 
14 (46.7) 
3 + 2.28 
12 (40.0) 
18 (60.0) 
5.27 + 1.67 
19 (63.3) 
11 (36.7) 
35.33 + 15.90 
21 (70.0) 
9 (30.0) 
1.17 + 0.34 
13 (43.3) 
17 (56.7) 
60.01 + 21.31 
20 (66.7) 
10 (33.3) 
2.37 + 0.99 
14 (46.7) 
11 (36.7) 
11 (46.7) 
10 (33.3) 
 
7 (23.3) 
7 (23.3) 
5 (16.7) 
4 (13.3) 
1 (3.3) 
 
100.27 + 21.22 
86.73 + 15.20 
25.40 + 4.34 
19.87 + 1.04 
120.07 + 25.71 
109.67 + 15.20 
76.33 + 12.59 
72.00 + 9.61 
90.91 + 16.19 
84.56 + 10.98 
1045.00 + 226.42 
1820.00 + 1135.45 
986.67 + 367.17 
1383.33 + 651.30 
 
 
 
1  
 
 
2  
 
 
17 
 
 
0.76 
 
 
34.72 
 
 
1 
 
 
 
 
 
 
 
 
 
 
 
50 
65 
20 
16 
80 
90 
60 
60 
66.67 
70 
500 
400 
500 
400 
 
 
 
7  
 
 
8 
 
 
71 
 
 
1.83 
 
 
118.40 
 
 
6 
 
 
 
 
 
 
 
 
 
 
 
168 
135 
40 
22 
180 
140 
100 
100 
126.67 
113,33 
1300 
6000 
2000 
3000 
Note: n = number of patients, SD = standard deviation, total patients = 30 patients, NYHA = New York Heart Association Functional Class, GFR = 
glomerular filtration rate, Admission = hospital admission, Discharge = hospital discharge, RR = respiratory rate, MAP = mean arterial 
pressure. 
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Table 3. Characteristics of drug therapy study subjects 
 
Drug Therapy (daily dose range) n = 30 Percentage (%) 
Standard therapy for heart failure: 
Furosemide (20-240 mg) 
- Furosemide 10 mg/hour infusion pump 
- Furosemide 5 mg/hour infusion pump 
- Furosemide 2.5 mg/hour infusion pump 
- Furosemide 3x20 mg IV 
- Furosemide 2x20 mg IV 
- Furosemide 1x20 mg IV 
- Furosemide 1x40 mg PO 
Hydrochlorothiazide (100 mg) 
Spironolactone (25-100 mg) 
- Spironolactone 2x50 mg PO 
- Spironolactone 1x50 mg PO 
- Spironolactone 1x25 mg PO 
Captopril (18.75-37.5 mg) 
- Captopril 3x12.5 mg PO 
- Captopril 3x6.25 mg PO 
Ramipril (2.5-5 mg) 
- Ramipril 1x5 mg PO 
- Ramipril 1 x 2.5 mg PO 
Lisinopril (2.5-10 mg) 
- Lisinopril 1x10 mg PO 
- Lisinopril 2x5 mg PO 
- Lisinopril 1x5 mg PO 
- Lisinopril 1 x 2.5 mg PO 
Valsartan (40-80 mg) 
- Valsartan 1x80 mg PO 
- Valsartan 1x40 mg PO 
Candesartan (16 mg) 
Bisoprolol (1.25-5 mg) 
- Bisoprolol 1x5 mg PO 
- Bisoprolol 1 x 2.5 mg PO 
- Bisoprolol 1x1,1,25 mg PO 
Other heart failure therapies: 
Digoxin (0.25-1 mg) 
ISDN (5-24 mg) 
Warfarin (2-4 mg) 
Dobutamine (3 mcg/kgBB) 
Dopamine (3 mcg/kgBB) 
Amiodarone (150-1200 mcg) 
Compliance with taking medication before hospitalization: 
Routine taking medication and control at Poly 
Not routinely taking medicine or never taking medicine before 
 
30 
5 
23 
14 
19 
7 
4 
5 
1 
27 
2 
4 
27 
9 
5 
4 
11 
6 
9 
5 
1 
2 
3 
1 
4 
1 
4 
1 
14 
2 
7 
8 
 
17 
13 
11 
3 
2 
1 
 
10 
20 
 
100.0 
16.7 
76.7 
46.7 
63.3 
23.3 
13.3 
16.7 
3.3 
90.0 
6.7 
13.3 
90.0 
30.0 
16.7 
13.3 
36.7 
20.0 
30.0 
16.7 
3.3 
6.7 
10.0 
3.3 
13.3 
3.3 
13.3 
3.3 
46.7 
6.7 
23.3 
26.7 
 
56.7 
43.3 
36.7 
10.0 
6.7 
3.3 
 
33.3 
66.7 
 
Note: 1 patient can receive more than 1 drug regimen, IV = intravenous, PO = orally. Standard therapy includes diuretics, aldosterone 
antagonists, ACEI, ARB, & beta blockers. Poly = Outpatient installation. 
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Fig. 1. Profile of cTnT serum levels before and after therapy. Note: total of patients = 30 
patients, cut off point cTnT = 12pg/ml, cTnT = cardiac Troponin T. 
 
 
 
Fig. 2. Profile of cTnT serum levels and symptoms improvement. 
 
 
Table 4. Characteristics of variations of standard therapy on study subjects 
 
Variant Standard Therapy n 
(Fur+/-Spi/Ram/Can/Bis) 
 
Furosemide, with or without 
Spinorolactone/Ramipril/Candesartan/Bisoprolol 
5 
(Fur+Spi+Cap/Val+/-Bis) Furosemide, Spironolactone, Captopril/Valsartan, with or without 
Bisoprolol 
5 
(Fur+Spi+Lis+/-Val+/-Bis) Furosemide, Spinorolactone, Lisinopril, with or without Valsartan and 
Bisoprolol 
5 
(Fur+Spi+Lis) Furosemide, Spironolactone, and Lisinopril 5 
(Fur+Spi+Ram+Bis) Furosemide, Spironolactone, Ramipril, and Bisoprolol 5 
(Fur+Spi+Cap+Bis) Furosemide, Spironolactone, Captopril, and Bisoprolol 5 
Note: total patients = 30 patients, total variants = 6 and each variant consists of 5 patients. 
Fol Med Indones, Vol. 56 No. 1 March 2020 : 4-14                                    Indrawijaya et al : Serum Troponin T Level in Standard Therapy Medication  
 
 10 
 
 
 
 
Fig. 3.  Profile of variations in standard therapy, medication adherence and cTnT levels. Note: total patients = 30 
patients. There are 6 variants of standard therapy and each drug variant consists of 5 patients. 10 patients 
regularly take medication and 20 patients do not routinely take medication before hospitalization. 
 
 
Table 5. Test results for different levels of troponin T data using the Wilcoxon signed ranks test 
 
N Parameter Mean + SD Signficance (p) 
30 CTnT levels before therapy vs 33.48 + 32.42 0.318 
CTnT levels after therapy 46.33 + 46.32 
 
 
Table 6. Results of different clinical symptoms with the Paired T test 
 
N Parameter Mean + SD Significance (p) 
30 
Pulse before therapy 100.27  + 21.22 
0.003 
Pulse after therapy 86.73  + 15.20 
30 
Systolic before therapy 120.07  + 25.71 
0.018 
Systolic after therapy 109.67  + 15.20 
30 
Diastolic before therapy 76.33  + 12.59 
0.019 
Diastolic after therapy 72.00  + 9.61 
30 
MAP before therapy 90.91  + 16.20 
0.011 
MAP after therapy 84.56  + 10.99 
30 
Fluid enters before therapy     1045.00  + 228.23 
0.470 
Fluid comes in after therapy   986.67  + 367.17 
30 
Fluid comes out before therapy   1820.00  + 1135.45 
0.114 
Fluid comes out after therapy  1383.33  + 651.30 
Note: the decrease in incoming and outgoing fluids is not statistically significant. 
 
 
Table 7. Results of different clinical symptoms data using the Wilcoxon signed ranks test 
 
N Parameter Mean + SD Significance (p) 
30 
RR before therapy 25.40 + 4.34 
0.000 
RR after therapy 19.87 + 1.04 
Note: the decrease in RR is statistically significant 
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Based on the characteristics of the patient's clinical 
condition, the mean pulse on the first and last day of 
hospitalization decreased from 100.27 + 21.22 to 86.73 
+ 15.20. The pulse target to return to a stable condition 
is <100x/minute (Valle et al 2011) and based on the 
reduction in the pulse rate has been fulfilled. In heart 
failure patients an increase in pulse at rest is caused by a 
continuous inhibition of vagal nerve activity which 
further increases sympathetic activity. A decrease in 
pulse 5x/minute can reduce the risk of mortality by 14% 
on the use of beta-blocker therapy. Decreased pulse can 
restore damage to left ventricular function so providing 
tachycardia in heart failure significantly improves heart 
function. Pulses above 100x/minute can cause cardiac 
dilatation due to increased ventricular filling pressure 
and activate neurohormonal (Hori & Okamoto 2012). 
 
The average respiratory rate (RR) on the first and last 
day of hospitalization decreased from 25.4 + 4.34 to 
19.86 + 1.04. The normal RR range in adults is 18-
20x/minute and based on the average RR last 
hospitalization has returned to normal. Patients with 
acute heart failure (NYHA FC III and IV) often with 
volume overload and discharge with diuretics can 
improve symptoms. An increase in RR at the time of 
hospitalization is consistent with a high class of heart 
failure patients and a decrease in RR is followed by a 
decrease in heart failure class. This is consistent with 
the results of the correlation test significantly in 
previous studies (Forleo et al 2015) namely the higher 
the RR the higher the NYHA class and the lower the left 
ventricular ejection fraction. 
 
 The mean systolic blood pressure on the first and last 
day of hospitalization decreased from 120.07 + 25.71 to 
109.67 + 15.19. The target of systolic blood pressure to 
return to a stable compensation condition is 90-120 
mmHg (Valle et al 2011) and based on average, the 
decrease in systolic blood pressure has met the target. 
At the time of hospital admission, congestive symptoms 
more often cause increased systolic blood pressure. 
Increased systolic associated with neurohormonal 
activation and cytokines thereby increasing afterload. 
Patients with increased systolic blood pressure upon 
admission have a better therapeutic response during 
hospitalization in acute heart failure. The higher the 
systolic blood pressure, the more therapies used such as 
ARB, ACEI, and beta blockers with antihypertensive 
effects (Gheorghiade et al 2006). 
 
The mean diastolic blood pressure on the first and last 
day of hospitalization decreased from 76.63 + 12.59 to 
72 + 9.61 mmHg. The target of reducing diastolic blood 
pressure is <80 mmHg (Manickasavagam et al 2009) 
and based on the average, the reduction in diastolic 
blood pressure has been fulfilled. 
 
The decrease in systolic blood pressure is greater than 
the decrease in diastolic blood. This is influenced by 
age, with increasing age, decreasing diastolic blood 
pressure will be smaller (Wang et al 2005). Systolic 
pressure, diastolic and mean arterial pressure (MAP) are 
important predictors of cardiovascular risk in patients 
younger than 60 years whereas patients over 60 years 
only systolic blood pressure and pulse pressure are 
associated with these risks (Domanski et al 1999). 
 
The mean of MAP on the first and last day of 
hospitalization was decreased from 90.91 + 16.19 
mmHg to 84.56 + 10.98 mmHg. Based on the results of 
the MAP calculation on the target of reducing blood 
pressure that is <130/80 (Manickasavagam et al 2009) 
obtained the MAP target <96.67 mmHg. Each reduction 
in MAP of 10 mmHg from the previous MAP predicted 
an 11% increase in mortality (Domanski et al 1999). 
Based on the average MAP, the reduction in MAP has 
met the MAP reduction target and no more than 10 
mmHg. 
 
Based on the profile of the volume of incoming and 
outgoing fluid (Figure 5.2), the mean volume of 
incoming fluid during the first and last day of 
hospitalization decreased, from 1045.00 + 226.42 to 
986.67 + 367.17. The average volume of discharge 
came out on the first day and the last day of 
hospitalization also decreased, namely from 1820.00 + 
1135.45 to 1383.33 + 651.30. Target diuresis to return 
to a stable condition (compensation) ie >1000 ml/24 
hours and repair fluid overload (Valle et al 2011). Based 
on the mean, diuresis (volume of fluid out) on the first 
and last day of hospitalization has met the target 
diuresis. Decrease in the volume of fluid in and out on 
the first and last day of hospitalization is affected by a 
decrease in diuretic dose on the last day of 
hospitalization adjusted for the response of diuresis of 
each different patient. 
 
According to Valle et al 2011, hydration status and 
myocardial performance in patients with complex heart 
failure. Based on an analysis of case by case shows each 
patient has its own hydration range for hyper or 
hypohydration which causes instability. The majority of 
patients with acute heart failure show good loop diuretic 
and vasoactive responses (Valle et al 2011). 
 
All patients received furosemide to treat fluid and salt 
retention, but not all patients received 5 standard 
therapeutic drugs. Some patients did not get 
spinorolactone due to hyperkalemia, some patients did 
not get ACEI because previous therapy (when 
outpatient) had received ARB or patients experienced 
coughing during hospitalization, and some patients did 
not get bisoprolol because there was still ronkhi and 
pulse and blood pressure which tended to be low. 
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Beta blockers (bisoprolol) are given to patients with 
mild to moderate symptoms but their use is not 
preceded when symptoms are severe (Nohria et al 
2002). A combination of furosemide and 
hydrochlorothiazide is also given to patients with low 
urine volume to increase output to the optimum. In 
addition to standard therapy, patients also get additional 
heart failure therapy. Digoxin is used to slow down 
rapid ventricular beats in atrial fibrillation or there is 
sinus rhythm (Ponikowski et al 2016). Warfarin as an 
oral anticoagulant is also given to patients with atrial 
fibrillation and LV thrombus to reduce 
mortality/morbidity and reduce the risk of venous 
thromboembolism (PERKI 2015, Ponikowski et al 
2016). Amiodarone is also indicated for atrial 
fibrillation in heart failure patients. Amiodarone 
controls heart rhythm and maintains sinus rhythm in 
patients with moderate-severe left ventricular 
dysfunction. Amiodarone is considered to control the 
pulse if the combination of beta-blockers and digoxin is 
inadequate (Khan et al 2013). 
 
Giving ISDN as a vasodilator in heart failure with 
comorbid coronary heart disease or LV thrombus and 
combined with ACEI/ARB because blood pressure 
remains high so that it requires more aggressive 
vasodilator therapy. Dopamine and dobutamine as 
inotropes and vasopressors are aimed at patients with a 
severe decrease in cardiac output (CO) which results in 
compromise of vital organ perfusion, where patients 
often show hypotension during acute heart failure 
(Ponikowski et al 2016). 
 
Dobutamine and dopamine both increase the cardiac 
index but dopamine results in a fairly long increase in 
pulse compared to dobutamine. Dopamine is not 
effective in reducing left-ventricular end-diastolic 
pressure but increases MAP while dobutamine does not 
increase MAP (Stoner et al 1977). 
 
Serial cTnT measurement can inform the therapeutic 
response and risk of further adverse events compared to 
a one-time check (baseline). Measurement of cTnT 
levels in heart failure can also look for the presence of 
acute myocardial infarction (IMA) type 1 although an 
increase and/or decrease in cTnT does not guarantee the 
presence of type 1 IMA (Mallick & Januzzi, 2015). 
According to Grodin and Tang 2013, an increase in 
cTnT levels in chronic heart failure is caused by a 
temporary or permanent mismatch of myocardial supply 
and needs so that cardiac troponin is released in acute 
and chronic conditions, the release of cTnT indicates an 
increase in cardiomyocyte changes that are worsening 
myocardial supply and needs so that cardiac troponin is 
released in acute and chronic conditions. an increase in 
cTnT explains how troponin T can be detected under 
conditions when metabolic requirements increase in 
supply (acute non-infarct myocardial) (Grodin & Tang 
2013). 
 
The limited number of patients in this study made a 
different test performed on troponin T levels before and 
after the therapy was done in a ratio. An increase in 
cTnT levels indicates ongoing myocyte injury 
associated with remodeling compared to infarction 
(Meredith et al 2016). In this study, there were no 
patients who used mechanical circulatory support so 
that the increase in troponin T after therapy showed a 
continuous myocyte damage toward remodeling. 
Decreased troponin T and NTproBNP levels may reflect 
improvements in ventricular wall stress and fewer 
myocardial damage (Takashio et al 2017). Unchanged 
troponin T levels indicate a steady state of 
decompensation and a longer duration of hospital stay 
(Ferreira et al 2014). 
 
Based on the different test on clinical symptom 
parameters, the mean decrease was statistically 
significant (p <0.05) from the pulse, RR, systolic blood 
pressure, diastolic blood pressure, and MAP. The 
decrease in these parameters shows a significant clinical 
improvement of heart failure (compensation). This is in 
accordance with the criteria for the return of the clinical 
condition of heart failure patients to a stable condition, 
namely systolic blood pressure 90-120 mmHg, pulse 
<100 x/min, diuresis> 1000ml/24 hours and 
improvement in fluid overload (Valle et al 2011). In the 
parameters of the volume of fluid in and out there is a 
decrease after therapy but the decrease is not 
statistically significant (p> 0.05). This is caused by the 
response of each patient's diuresis is individual while 
based on the mean there is a decrease in the volume of 
fluid in and out due to a decrease in the dose of 
furosemide until the end of hospitalization. 
 
Overload volume that develops into hemodynamic and 
congestive has a complex pathophysiological process. 
Several factors are involved in the accumulation and 
redistribution of fluid with a longer time in the 
interstitial and intravascular compartments, causing 
congestion. Water and salt retention in the kidney 
initiates mechanisms that contribute to fluid 
accumulation but are redistributed by the abdominal 
venous reservoir due to changes in cardiopulmonary 
vascular capacity (Miller 2016). 
 
Based on the profile variation of standard therapy, 
medication adherence, and serum cTnT levels, patients 
with a history of regularly taking medication have 
decreased levels and patients with a history of not 
routinely taking medication have increased levels of 
cTnT. In the study of Wal et al in 2005, non-compliance 
with medication/diet is a factor with a large enough 
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percentage (15-64%) to worsen the condition of heart 
failure. 
 
Patients with a routine history of taking medication had 
lower heart failure worsening in this study. This was 
indicated by a significant decrease in cTnT levels in 10 
patients in this study. In the study of Miller et al (2009), 
the more frequent cTnT examination in outpatients with 
chronic heart failure that showed an increase in cTnT (> 
10 pg/ml) was associated with an increased risk of 
short-term mortality or heart transplantation and also 
hospitalization of patients. Troponin T levels after 
therapy in hospitalized patients in this study can be a 
baseline for measuring patients troponin T levels at the 
next outpatient. 
 
There was a slight decrease in cTnT levels in some 
standard therapy variants that received ARB. 
Comparison of ACEI and ARB in heart failure patients 
with LVEF <40% does not show a significant mortality 
difference between the two. In addition, the comparison 
of ACEI and ARB also did not differ significantly on 
length of stay, but drug withdrawal due to side effects 
on ARB was significantly smaller than ACEI (Heran et 
al 2012). Based on Val-HeFT and CHARM studies, the 
addition of ARBs to a single ACEI in patients with heart 
failure does not improve survival. There were no 
significant differences in total mortality, cardiovascular 
mortality or non-cardiovascular mortality 
 
 
CONCLUSION 
 
There were no significant changes between troponin T 
levels before and after treatment. Insignificant changes 
mean no worsening of myocardial damage. There are 
significant changes, namely a decrease between blood 
pressure, MAP, pulse, and RR before and after 
administration of therapy. Significant reduction means 
improvement in symptoms. 
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